Philadelphia, Pennsylvania-Biomedical company PolyMedix Inc. has received a US Patent for use of 'facially amphiphilic polymers as anti-infective agents.'
PolyMedix is an emerging company focused on developing acute care products for infectious diseases and acute cardiovascular disorders.
The company's patent claims that it has developed a method of producing polymers and oligomers with amphiphilic surfaces. Amphiphilic means containing both hydrophilic and hydrophobic parts (liking and not liking water)
The patent also claims that PolyMedix has developed antimicrobial material compositions, methods of killing microorganisms, processes of producing antimicrobial surfaces and improved devices containing the claimed polymers or oligomers. Such devices include catheters, contact lenses, plastic devices, medical devices or implants and non-woven or woven fabrics, said PolyMedix.
The polymers can inhibit the growth of microorganisms in contact with the surface or in areas adjacent to the biocidal surface, the company says. PolyMedix also says it has developed a method of identifying and optimising the facial amphiphilicity of polyamide, polyester, polyurea, polyurethane, polycarbonate and polyphenylene polymers.
PolyMedix focuses on developing novel drugs and biomaterials for treating infectious diseases and acute cardiovascular disorders. Its compounds are based on biomimetics, which are non-peptide small-molecule drugs that mimic the activity of proteins."